Biome Australia (BIO) investor relations material

Executive summary

• Achieved record H1 FY26 sales revenue of AUD 12.4 million, up 40% year-over-year, with Q2 revenue at AUD 6.48 million and a rolling 12-month run rate of up to AUD 25.9 million.

• Net profit after tax was AUD 1.18 million, up 172% year-over-year, with eight consecutive quarters of positive EBITDA.

• Maintained gross margin above 61% and EPS rose 165% to AUD 0.53.

• Distribution expanded to over 7,000 points in Australia, targeting 7,500 by year-end, with international expansion in Canada, Ireland, UK, and New Zealand.

• Practitioner-only model and premium positioning drive high customer loyalty and repeat purchases.

Financial highlights

• Revenue grew 40% year-over-year to AUD 12.4 million; cash receipts up 62% from H1 2025.

• Adjusted EBITDA reached AUD 1.47 million, up 100% year-over-year; net profit increased by 172%.

• Gross profit reached AUD 7.58 million, with gross margin at 61.1%.

• Operating cash flow of AUD 2.09 million, a turnaround from a prior year outflow; borrowings reduced by AUD 1.4 million.

• EPS increased to AUD 0.53, up 165% year-over-year.

Outlook and guidance

• On track to meet Vision 27 three-year plan, targeting AUD 80 million in cumulative sales.

• Winter Immunity Campaign and first major national advertising campaign to drive H2 growth.

• International sales targeted to exceed 10% of total, with long-term goal of equal market size in Australia, Europe, and North America.

• Ongoing clinical trial for proprietary BMB18 strain expected to support future product development.

• Continued investment in sales and marketing to support domestic and international growth.